Bellicum Pharma (BLCM) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. BROS
3. ARM
4. FIS
5. QCOM
6. EXPE
7. CPAY
8. PAYC
9. SNAP
10. FSLY

Go back to Bellicum Pharma (BLCM) Misses Q4 EPS by 3c

Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

March 13, 2017 4:05 PM EDT

On track to complete enrollment in E.U. registration trials for BPX-501 and rimiducid this year

Reported updated clinical data with BPX-501 demonstrating rapid immune recovery and low rates of GvHD in children with blood cancers and orphan inherited blood disorders

Initiated clinical trials of controllable CAR T and TCR product candidates 

Management to host conference call and webcast today at 5 p.m. Eastern

HOUSTON, March 13, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing... More